CANNAPHARMARX, INC.
Datakwaliteit: 100%
CPMD
OTC
Manufacturing
Chemicals
€ 0,00
▲
€ 0,00
(22,58%)
Marktkapitalisatie: 2,71 M
Prijs
€ 0,00
Marktkapitalisatie
2,71 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Negative free cash flow of -794.621,0
Capital efficient — spends only 0,41% of revenue on capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)66,09%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROICN/A
Net Margin-817,19%
Op. Margin-245,77%
Veiligheid
Debt / Equity
N/A
Current Ratio0,05
Interest Coverage-1,71
Waardering
PE (TTM)
-0,24
Boven sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,2 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,3 |
| Net Margin % | -817,2 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 66,09% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1,36 M | Net Income (TTM) | -11,13 M |
| ROE | N/A | ROA | -96,42% |
| Gross Margin | -153,06% | Operating Margin | -245,77% |
| Net Margin | -817,19% | Free Cash Flow (TTM) | -794.621,0 |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,05 |
| Interest Coverage | -1,71 | Asset Turnover | 0,12 |
| Working Capital | -27,01 M | Tangible Book Value | -22,52 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,24 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 1,99 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -29,28% | ||
| Market Cap | 2,71 M | Enterprise Value | 2,71 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,02 | Revenue / Share | 0,00 |
| FCF / Share | 0,00 | OCF / Share | 0,00 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,41% | FCF Conversion | 7,14% |
| SBC-Adj. FCF | -794.621 | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 1,36 M | 820.137,0 | 0,0 | 0,0 | 0,0 |
| Net Income | -11,13 M | -9,91 M | -8,53 M | -8,83 M | -19,89 M |
| EPS (Diluted) | -0,02 | -0,02 | 0,04 | — | — |
| Gross Profit | -2,08 M | -2,93 M | — | — | — |
| Operating Income | -3,35 M | -3,61 M | -5,21 M | -2,99 M | -14,49 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — |
| SG&A Expenses | — | 116.640,0 | — | — | — |
| D&A | — | 0,0 | 294.934,0 | 2.708,0 | 128.505,0 |
| Interest Expense | 1,96 M | 2,26 M | 2,29 M | 1,51 M | 2,29 M |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 7,02 M | 10,84 M | 5,41 M | 114.330,0 | 8,75 M |
| Total Liabilities | 37,17 M | 30,65 M | 22,76 M | 13,04 M | 17,55 M |
| Shareholders' Equity | -30,15 M | -19,81 M | -17,34 M | -12,93 M | -8,80 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 1.804,0 | 2.156,0 | 2.317,0 | 27.767,0 | 334.969,0 |
| Current Assets | 1,31 M | 1,02 M | 100.014,0 | 29.538,0 | 467.551,0 |
| Current Liabilities | 31,59 M | 25,75 M | 17,17 M | 13,04 M | 17,55 M |
{"event":"ticker_viewed","properties":{"ticker":"CPMD","listing_kind":"stock","pathname":"/stocks/cpmd","exchange":"OTC","country":"US"}}